SUVN-911 is an novel chemical entity intended for treatment of major depressive disorder
Suven Life Sciences announced that their NCESUVN-911, a potent, selective, brain penetrant and orally active, novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing under US IND 133850 and the topline results from the study is expected during the quarter Jan-March 2018.Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031 and Phase 1 completed SUVN-D4010 for Alzheimer's disease and Schizophrenia. SUVN-911 is the 4th developmental molecule from Suven's drug discovery pipeline with proprietary intellectual property (Patents) and US IND. In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
